Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply

JAMA. 2017 Sep 19;318(11):1067-1068. doi: 10.1001/jama.2017.11517.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Product Surveillance, Postmarketing*
  • Safety
  • United States
  • United States Food and Drug Administration*